Navigation Links
Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Date:9/15/2011

endpoint (p-value 0.005) in the Company's previous Phase 3 study as a clinically significant outcome following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment). The SUPPORTS trial was conducted at major transplant centers throughout the US, Europe, and Australia. The trial was the subject of a Special Protocol Assessment (SPA) agreement that the Company reached with the US Food and Drug Administration (FDA). It was determined in a pre-specified interim analysis that this study was unlikely to achieve the primary efficacy objective.

orBec® was the subject of two prior randomized, double-blind, placebo-controlled clinical trials in acute GI GVHD. The first study was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139).  At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... British Columbia and MENLO PARK, Calif. ... (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol ... trial had been filed with the U.S. Food and Drug ... 50mg/m 2 has been opened at three clinical trial ... company also confirmed that gross proceeds of US$2.9 million have ...
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
(Date:8/18/2014)... Israel , Aug. 19, 2014 Immune ... Stockholm : "IMNP"), a biotechnology company, today announced ... its common stock on the NASDAQ Capital Market has been ... NASDAQ OMX Group. IMMUNE,s common stock is expected to begin ... trading on August 21, 2014 under the symbol IMNP. ...
Breaking Medicine Technology:DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
... Miami HEAT forward Juwan Howard and Basketball Hall of Famer ... for Adolescent Health and Medicine (SAHM) today to bring ... for Teens is a national awareness campaign designed to ... against serious and potentially life-threatening diseases. To ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT ... of probiotics products in China, today reported its unaudited financial results ... year ended December 31, 2010. Third ... Net sales increased 39.0% y-o-y to $32.4 million; ...
Cached Medicine Technology:Miami HEAT Forward Juwan Howard and NBA Legend Bob Lanier Join Vaccines for Teens Educational Campaign to Urge Local Teens to Take Their Best Shot at Health 2Miami HEAT Forward Juwan Howard and NBA Legend Bob Lanier Join Vaccines for Teens Educational Campaign to Urge Local Teens to Take Their Best Shot at Health 3Miami HEAT Forward Juwan Howard and NBA Legend Bob Lanier Join Vaccines for Teens Educational Campaign to Urge Local Teens to Take Their Best Shot at Health 4Miami HEAT Forward Juwan Howard and NBA Legend Bob Lanier Join Vaccines for Teens Educational Campaign to Urge Local Teens to Take Their Best Shot at Health 5China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 2China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 3China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 4China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 5China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 6China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 7China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 8China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 9China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 10China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011 11
(Date:8/20/2014)... 20, 2014 Hope For The Warriors® ... Celebration to be hosted in Washington, DC on Thursday, ... This signature event honors the courage of our wounded ... fallen. Proceeds from the Got Heart, Give Hope® Celebration ... dedicated to restoring a sense of self, restoring the ...
(Date:8/20/2014)... WA (PRWEB) August 20, 2014 “Have you ... an auto accident and personal injury lawyer serving the greater ... that incident? If so, then keep reading . , ... that individuals injured in an auto accident can use to ... Jones explains that a personal injury insurance claim will allow ...
(Date:8/20/2014)... The “Human Insulin Market by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2019” provides a ... current market trends,and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
(Date:8/20/2014)... Burlingame, CA (PRWEB) August 20, 2014 ... publishers to speech-enable their websites and create a new ... users to consume content by listening to a narration ... in multiple reader genders and languages. Users can ... work, check social networks, while consuming content. ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 Over ... the Global Bureau of Disease, low back pain is the ... the most common reasons for missed work. Americans spend at ... this pain. , Most cases of back pain are not ... mechanical (non-organic) origin. , For example, Pete, a busy accountant, ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2
... diagnosis, treatment, researchers say , MONDAY, Oct. 5 (HealthDay News) ... on the diagnosis and treatment of one of the most ... new genes associated with head and neck cancer. , Previously, ... and neck cancer, which includes cancers of the mouth, nose, ...
... ... of growth charts/BMI, Children,s National pediatrician stresses the need for clear communication about seriousness ... ... explain the seriousness of a child being overweight may not be reaching the child,s ...
... Oct. 5 With the school season underway, New York ... to please organize blood drives at their schools, a process ... learning experience for both students and the surrounding community. , ... Brothers, a middle school educator. Now in its ...
... 5 Vocollect Healthcare Systems, Inc. and American ... contribute towards a more timely and unified Electronic ... This alliance interfaces the market,s top performing interactive ... software and EMR offering. , The ...
... In conjunction with its celebration of Case Management Week (Oct. ... the winner of its second annual $1,000 Patricia McCollom Scholarship ... of Fort Bragg, N.C. A case manager with the Army,s ... a highly qualified field of nominees who had either applied, ...
... than 7,000 people are diagnosed with head and neck cancer ... in death. These cancers include tumours of the mouth, ... to the sexually transmitted infection, HPV-16. Scientists at Liverpool ... to look for genes that indicated infection. The ...
Cached Medicine News:Health News:Gene Discovery May Advance Head and Neck Cancer Therapy 2Health News:Pediatrics: Doctors Must Find Better Ways to Talk To Parents about Childhood Obesity 2Health News:Pediatrics: Doctors Must Find Better Ways to Talk To Parents about Childhood Obesity 3Health News:Blood Drives Offer Lessons in Learning 2Health News:Blood Drives Offer Lessons in Learning 3Health News:American HealthTech and Vocollect Healthcare Systems Announce an Alliance to Deliver Unified Electronic Medical Records 2Health News:American HealthTech and Vocollect Healthcare Systems Announce an Alliance to Deliver Unified Electronic Medical Records 3Health News:CCMC Celebrates Case Management Week (Oct. 11-17) With Second Annual Patricia McCollom Scholarship 2Health News:DNA test could be key to targeting treatments for head and neck cancer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: